GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunshine Biopharma SBFM · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.70

-4.93%

Close of 13 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Sunshine Biopharma — daily SBFM Delayed
Market value
$1.9m
Last close × shares
Volume
31.7k
Shares, 13 Nov 2026

About Sunshine Biopharma

From its filings with the US Securities and Exchange Commission

SEC filings

Sunshine Biopharma is based in Fort Lauderdale, Florida and is incorporated in Colorado. Its shares trade on Nasdaq under the ticker SBFM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $36.3m and a net loss of $6.0m. At that date it held total assets of $30.1m and shareholders' equity of $23.0m.

In its own words

In-licensing and Supply Agreements: Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by purchasing the drug dossiers from strategic partners. Nora Pharma then files the dossiers with Health Canada to obtain regulatory approval prior to marketing. The approval process at Health Canada takes on average of 12 months. The products are sold under Nora Pharma label.

Cross-licensing: Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by receiving an authorization letter from pharmaceutical partners. The partners’ products are already approved in Canada but we are still required to obtain our own approval from Health Canada, which takes on average 45-60 days. The products are sold under Nora Pharma label.

Distribution Agreements: Nora Pharma acquires the rights to market, sell and distribute the products in Canada by signing a distribution agreement with pharmaceutical partners. The partners’ products are already approved by Health Canada. The products are sold under the partners’ label.

On April 20, 2022, we filed a provisional patent application in the United States covering our K1.1 mRNA molecules.

Quoted from its 10-K, filed 3 Apr 2026. Read the filing on SEC.gov ↗

More about Sunshine Biopharma →

Latest on Sunshine Biopharma

Our reporting

Next results

12 Nov 2026

Due on 12 Nov 2026. Analysts expect earnings of -3.40 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Sunshine Biopharma's ticker?

Sunshine Biopharma trades as SBFM on its US listing, under ISIN US8677817004.

What was Sunshine Biopharma's last closing price?

2.70 on 13 Nov 2026. The figure is in USD and is never converted.

When does Sunshine Biopharma next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.